Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
CROSSMARK LOGO Buy Reprints
PDF

Translate this page into:

Observation Letter
87 (
3
); 416-420
doi:
10.25259/IJDVL_591_19
pmid:
33871206

Melanoma arising in a giant congenital melanocytic nevus with neuroblastoma RAS mutation

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
Departmet of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
Corresponding author: Dr. Neetu Bhari, Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi - 110 029, India. drntbhari@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Dudani P, Senthilnathan G, Wajid MA, Gupta AK, Kaushal S, Arora S, et al. Melanoma arising in a giant congenital melanocytic nevus with neuroblastoma RAS mutation. Indian J Dermatol Venereol Leprol 2021;87:416-20.

Sir,

Malignant melanoma is uncommon in Asian population and pre-pubertal incidence is extremely rare. Pediatric melanoma is not a congener of adult melanoma with varying risk factors, morphology, behavior and prognosis.1 Congenital melanocytic nevi are recognized risk factors for melanoma, directly proportional to their number.2

A four-year-old girl presented with a rapidly growing hyperpigmented nodule on her back, within her large congenital melanocytic nevus, for the past four months. It was extremely tender on palpation and associated with occasional bleeding following minor trauma. There were no other systemic complaints and family history was unremarkable.

Clinical examination revealed a single, large melanocytic nevus (>20 cm diameter) on her back (Fitzpatrick type 3 skin), along with multiple satellite nevi sized 0.5–8 cm. The overlying nodule (8 cm x 7 cm x 4 cm) was sessile, lobulated and erythematous to variegate hyperpigmented [Figure 1]. We noted focal areas of ulceration and superficial hemorrhages on its surface. Both nodule and surrounding skin were distinctly tender. There was no clinical lymphadenopathy or hepatosplenomegaly. Dermoscopy of the nodule showed lobulated surface with peripheral linear and curved vessels, ulceration, blue white veils, depigmented areas and yellow-orange homogenous areas with yellow-brown crusting [Figure 2].

Figure 1:: Ulcerated lobulated nodule of size 8 cm × 7 cm × 4 cm present over congenital melanocytic nevus of size 20 cm over the back with multiple satellite nevi of size 0.5–8 cm
Figure 2:: Dermoscopic analysis of the nodule (DermLite 4, polarized, 10x, magnified) shows lobulated surface with surface linear and curved vessels (red arrow), ulceration, blue-white veils (black arrow), depigmented areas and yellow-orange homogenous areas with yellow-brown crusting

Biopsy of the nodule revealed invasive neoplastic cells arranged in sheets. These cells contained abundant eosinophilic cytoplasm, round to oval nuclei with nuclear pleomorphism, prominent nucleoli, occasional nuclear pseudo-inclusions and multiple atypical mitoses; diagnostic of malignant melanoma [Figures 3a and b]. Immunohistochemistry showed diffuse cytoplasmic positivity for HMB 45 (anti-gp100) and Melan-A [Figures 3c and d]. Positron emission tomography showed lesional uptake along with a small adjacent focus and solitary left axillary lymph node [Figures 4a and b]. Excision biopsy from the latter also showed tumor deposits [Figure 5a].

Figure 3a:: Histopathology of the nodule shows an invasive tumor predominantly arranged in sheets (H and E, ×100)
Figure 3b:: Higher magnification shows melanoma cells with abundant eosinophilic cytoplasm, prominent nucleoli and occasional nuclear pseudoinclusions (H and E, ×400)
Figure 3c:: On immunohistochemistry, the tumor cells show diffuse cytoplasmic positivity for HMB 45 (IHC, DAB chromogen, ×200)
Figure 3d:: On immunohistochemistry, the tumor cells show diffuse cytoplasmic positivity for Melan A (IHC, DAB chromogen, ×200)
Figure 4a:: Maximum intensity projection of fused 18F-fluorodeoxyglucose positron emission tomography/computed tomography images showing heterogeneous mass measuring 2.5 cm × 4.4 cm in the left posterior chest wall with increased fluorodeoxyglucose uptake (maximum standardized uptake value – 73.9) (white arrow)
Figure 4b:: Maximum intensity projection, of fused 18F-fluorodeoxyglucose positron emission tomography/computed tomography images showing enlarged left axillary lymph node measuring 1.8 cm × 1.2 cm with increased FDG uptake (maximum standardized uptake value – 42.1) (white arrow). *Standardized uptake value
Figure 5a:: Histopathology of the excised lymph node showing proliferation of atypical melanocytic cells in the dermis (H and E, ×200)
Figure 5b:: Margin of the excised nodule shows a dermal nevus with melanin pigment (H and E, ×400)

Magnetic resonance imaging of brain was unremarkable. Her disease was Stage III, as per American Joint Committee on Cancer staging. Genetic mutational analysis revealed a missense mutation in neuroblastoma RAS viral oncogene (NRAS) gene (chr1:115256529:T>A:c.182A>T, p.Gln61Leu/ Exon3). No mutations were detected in proto-oncogene B-Raf (BRAF) and c-kit (receptor tyrosine kinase) genes.

The nodule was surgically excised along with a 1 cm margin. Histopathology of excised specimen showed tumor-free margins [Figure 5b]. We administered an induction therapy of 20 million IU/m2, interferon alpha 2b, five days per week for four weeks. Maintenance therapy consisted of 10 million IU per m2, interferon alpha 2b, three times per week along with injection nivolumab (3 mg/kg) once in four weeks for three cycles (12 weeks). Thereafter, we advised palliative care as new lymph nodes became palpable suggestive of disease relapse. She survived for 4 months after discontinuing chemotherapy.

Giant congenital melanocytic nevus is characterized by a diameter exceeding 20 cm by adulthood and is associated with 5-40% life-time risk of developing melanoma at the lesional site, most occurring within the first 5 years of life.3,4 Neuromelanosis and melanoma are more likely with size >40 cm, number >20 or multiple satellite lesions and a truncal location. A gadolinium-enhanced screening magnetic resonance imaging (MRI) of the brain and whole spine is recommended <1 year age in a child presenting with this condition.4,5 If found normal, annual neurodevelopmental monitoring should be done until school age for early detection of developmental aberrations such as speech delay. Any abnormality on MRI should prompt a regular clinical and radiological evaluation. Family members of such a child should be educated about regular self-examination of skin and to report any new lesion, secondary surface change or rapid growth of existing lesion. This reported lesion should be observed for four weeks with baseline photographs. In case of progression or development of other abnormalities like lymphadenopathy, excision biopsy should be performed.

There is no accepted standard treatment for this condition, and surgical excision remains controversial. Surgery fails to address the risk of extracutaneous melanoma, however, removal of melanocytic cells may reduce risk of developing melanoma within the nevus. Flaps or pigmented excised epidermis may be used for reconstruction following staged surgical excision. Alternate treatment options include combinations lasers (diode, fractional carbon dioxide and q-switched Nd-YAG lasers) and curettage.4,6,7

Compared to adults, pediatric melanomas have more atypical features, thicker lesions at diagnosis, higher frequency of nodular histotype and more aggressive course [Table 1].1 A mutational analysis concluded that sun-induced pediatric melanomas exhibit a UV-induced mutational spectrum similar to its adult counterpart (telomerase reverse transcriptase-promoter (TERT-p), BRAF V600 and phosphatase and tensin homolog (PTEN) mutations). NRAS mutation is more frequent in melanomas arising within congenital melanocytic nevi,8 also seen in our patient.

Table 1:: Comparison of adult and pediatric melanoma1,8,9
Adult Pediatric
Site Typical – photoexposed, acral Lower limbs
Etiology Sun exposure Sun exposure for sporadic, genetic predisposition for familial cases and those arising within CMN
Mutation BRAF V600 (60%)
NRAS (20%)
Sporadic (BRAF V600, PTEN)
Familial (CDKN2A, CDK4)
CMN-associated: NRAS, PTEN
Diagnostic features ABCDE (sensitivity 58%–76%) ABCDE misleading, >50% amelanotic
Thickness at presentation Less More
Progression Slow Rapid
Lymph node metastasis Later Earlier, in 50%–70% of borderline lesions
Prognosis Poor Relatively better (age<10 years)

ABCDE: Asymmetry, border irregularity, color variation, diameter greater than 6 mm and evolving size, shape or color. BRAF: Proto-oncogene B-Raf, NRAS: Neuroblastoma RAS viral oncogene, PTEN: Phosphatase and tensin homolog, CDKN2A: Cyclin-dependent kinase inhibitor 2A, CDK4: Cyclin-dependent kinase 4, CMN: Congenital melanocytic nevi

On dermoscopy of the nodule, we observed blue-white veil, linear peripheral vessels and depigmented areas; suggestive of nodular melanoma.9,10 Multiple authors have reported a more aggressive course and sentinel lymph nodal metastases in young children as compared to adults, however, their survival rate remains better than post-pubertal and adult patients.3 Our patient also showed a rapid progression and lymph node involvement. Specific guidelines are lacking concerning management of melanoma arising in a congenital melanocytic nevus. Lesional surgical excision with adjuvant chemotherapy remains the treatment of choice. Choice of adjuvant in children is based on adult studies, as data are scarce in the former group. Nivolumab was approved by the US Food and Drug Administration (FDA) in December 2017 for adjuvant therapy of cutaneous melanoma with lymph node metastasis and Stage IV disease post-definitive resection of lesion(s). Other adjuvants used for this indication include pembrolizumab, ipilimumab and interferon alpha. We selected nivolumab for its ability to prolong relapse-free survival with reduced systemic toxicity compared to ipilimumab, in patients with resected stage III/IV melanoma at high risk of recurrence.11

Acknowledgment

We thank Dr. S.V.S. Deo and his team at Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, for the surgical excision of tumor.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , , et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115:649-54.
    [CrossRef] [PubMed] [Google Scholar]
  2. , . Melanoma in children and adolescents. Diagnostic Histopathol. 2008;14:18-27.
    [CrossRef] [Google Scholar]
  3. , , , . Congenital melanocytic nevi: Clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005;52:197-203.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Melanoma arising in a Giant congenital melanocytic nevus: Two case reports. Diagn Pathol. 2019;14:21.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Melanoma in congenital melanocytic naevi. Br J Dermatol. 2017;176:1131-43.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , . Giant congenital melanocytic nevi successfully treated with combined laser therapy. Indian Dermatol Online J. 2020;11:79-82.
    [Google Scholar]
  7. , . Curettage of giant congenital melanocytic nevi in neonates: A decade later. Arch Dermatol. 2002;138:943-7.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , , , , et al. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol. 2015;135:816-23.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Melanoma in the young: Differences and similarities with adult melanoma: A case-matched controlled analysis. Cancer. 2007;110:614-24.
    [CrossRef] [PubMed] [Google Scholar]
  10. , , , , , , et al. Dermoscopic evaluation of nodular melanoma. JAMA Dermatol. 2013;149:699-709.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , , , , , et al. Adjuvant nivolumab versus ipilimumab in resected Stage III or IV melanoma. N Engl J Med. 2017;377:1824-35.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
873

PDF downloads
339
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections